GlassScriptPhysician profile
Amrew Al-Ahmad
NPI 1710203815
$12,701.23
in general payments reported to CMS, 2019-2025
30 companies · $9,718 in 2025
The $9,718 reported for 2025 was more than what 92% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2020: $255 · 2021: $139 · 2022: $475 · 2023: $1,437 · 2024: $677 · 2025: $9,718.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Education: $7,000 · Food and Beverage: $3,419 · Travel and Lodging: $1,212 · Consulting Fee: $200.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Education | $7,000.00 |
| Food and Beverage | $3,419.43 |
| Travel and Lodging | $1,211.92 |
| Consulting Fee | $200.00 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intuitive Surgical, INC. | $8,258.43 | 2025 | |
| Abbvie INC. | $760.28 | 2022-2024 | Teflaro, Avycaz, Dalvance |
| Astrazeneca Pharmaceuticals LP | $500.19 | 2021-2025 | Fasenra, Tezspire, Airsupra |
| Glaxosmithkline, LLC. | $338.63 | 2024-2025 | Trelegy Ellipta, Nucala |
| Mylan Specialty L.P. | $326.90 | 2022-2024 | Yupelri |
| Bayer Healthcare Pharmaceuticals INC. | $325.00 | 2020-2023 | |
| Insmed, INC. | $320.58 | 2024-2025 | Arikayce, Brinsupri |
| Janssen Pharmaceuticals, INC | $279.25 | 2023-2024 | Xarelto |
| Inspire Medical Systems, INC. | $255.02 | 2023-2025 | Inspire |
| Regeneron Healthcare Solutions, INC. | $253.84 | 2023-2025 | Dupixent |
| Electromed, INC. | $230.68 | 2022-2025 | Smartvest |
| Actelion Pharmaceuticals US, INC. | $173.98 | 2022-2024 | Opsumit, Uptravi |
| Abbott Laboratories | $125.78 | 2020-2022 | |
| Amgen INC. | $86.02 | 2024-2025 | Tezspire |
| Verona Pharma, INC. | $48.28 | 2025 | Ohtuvayre |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| United Therapeutics Corporation | $45.46 | 2022 | |
| Merck Sharp & Dohme LLC | $43.41 | 2020-2025 | Zerbaxa |
| Pulmonx Corporation | $41.65 | 2023-2024 | Zephyr Endobronchial Valve, Chartis Catheter, Pulmonx Chartis Tablet Console |
| Baxter Healthcare | $35.43 | 2023 | Hillrom - Life 2000 Ventilation System |
| Philips North America LLC | $33.80 | 2025 | Incourage Airway Clearance Therapy, Vest Therapy Und |
| Genzyme Corporation | $33.16 | 2023-2024 | |
| Inogen, INC. | $27.20 | 2023 | Inogen One G5 Oxygen Concentrator - Bluetooth |
| Viatris Specialty LLC | $25.78 | 2025 | Yupelri |
| Grifols USA, LLC | $23.06 | 2022 | |
| Gilead Sciences, INC. | $19.78 | 2024 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $19.39 | 2023 | Stiolto Respimat |
| Mallinckrodt Hospital Products INC. | $19.38 | 2025 | Acthar |
| Ani Pharmaceuticals, INC. | $18.39 | 2025 | Purified Cortrophin Gel |
| Melinta Therapeutics, LLC | $16.60 | 2023 | Vabomere |
| Amneal Pharmaceuticals LLC | $15.88 | 2025 | Alymsys |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Amrew Al-Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.